Leading the hunt for a COVID-19 vaccine
Paul Stoffels, J&J ’s Chief Scientific Officer, has given delegates at eyeforpharma’s Barcelona Virtual conference exclusive insights into its rapid progress in the search for a vaccine to the COVID-19 virus. Speaking to Reuters News on day two of the five-day conference, Stoffels said J&J ’s potential vaccine, which has just been chosen as a lead candidate to help tackle the pandemic, could be ready for clinical trials as soon as early September with evidence of its safety and efficacy expected by the end of the year. This means that the first vaccinations could be given in the first quarter of 2021. J&J hopes to have developed millions of batches by then, enabling vaccines for high-risk people under emergency use, Stoffels added. The company is also expanding the its global manufacturing capacity to assist in the rapid production of a vaccine that will enable the supply of more than one billion doses of the vaccine globally. J&J said it would do this on a not-for-profit basis for emergency pandemic use. Extensive testingIn the interview with Alex Threlfall, Reuters Editor at Large, Stoffels expressed high confidence in the vaccine ’s potential. “We have done this several times with HIV, RSV, Zika and Ebola. Four times we have been able to use the vector, inserting the right piece of DNA coding for the particular antigen for that disease. We have vaccinated 50,000 people so far in these four diseases.&n...
According to a study published inThe Journal of Clinical Endocrinology& Metabolism, obesity is not associated with an increased risk of developing thyroid disease or thyroid cancer.Endocrinology Advisor
According to a study published in theInternational Journal of Cancer, light pollution at night time may increase breast cancer risk by 10% in post-menopausal women.inews
As of April 21, 2020, more than 2.5 million cases of coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, have been reported in 210 countries and territories, with the death toll at 171,810. Both chloroquine and hydroxychloroquine have gained considerable media attention as possible therapies, resulting in a significant surge in demand. In overdose, both medications can cause severe, potentially life-threatening effects. Here, we present a brief overview of the pharmacology of chloroquine and hydroxychloroquine, manifestations of toxicity, and treatment considerations.
The coronavirus disease 2019 (COVID-19), seems to have a cardiovascular tropism characterized by high incidence of myocardial infarction especially for patients with severe infections recovered in intensive care units. In their letter, the Authors state that oxidative stress could play a pivotal role to determine cardiovascular complications in COVID-19. We agree about this issue. In particular, NADPH oxidase-2 (NOX-2), that it is considered one of the most important sources of superoxide anion in human , plays a role in systemic inflammation and pathogenesis of several RNA virus as the influenza virus .
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Conferences | COVID-19 | Ebola | Ebola Vaccine | Emergency Medicine | Harvard | Israel Health | Middle East Health | Pandemics | Partnerships | Pharmaceuticals | Profits and Losses | Vaccines | Veterinary Vaccinations | Zika Virus